Federal Trade Commission
10/20/2021 | Press release | Distributed by Public on 10/20/2021 10:49
Title: Nordic Clinical, Inc. and Encore Plus Solutions, Inc. (Federal)
Nordic Clinical, Inc. and Encore Plus Solutions, Inc.
Tags:
Last Updated: October 20, 2021
Case Status:
Pending
Federal Trade Commission, Plaintiff v. Mile High Madison Group, Inc., a Delaware corporation; Nordic Clinical, Inc., a Delaware corporation; Encore Plus Solutions, Inc., a Florida corporation; Le Groupe Mile High Madison, Inc., a Quebec corporation; Clinique Nordique, Inc., a Quebec corporation; Vittorio DiCriscio, individually and as an officer, director, or control person of Mile High Madison Group, Inc., Nordic Clinical, Inc., Encore Plus Solutions, Inc., Le Groupe Mile High Madison, Inc., and Clinique Nordique, Inc.; and Vito Proietti, individually and as an officer, director, or control person of Mile High Madison Group, Inc., Nordic Clinical, Inc., Encore Plus Solutions, Inc., Le Groupe Mile High Madison, Inc., and Clinique Nordique, Inc., Defendants.
FTC Matter/File Number:
172 3132
172 3143
Civil Action Number:
1:20-cv-21622-FAM
Enforcement Type:
Civil Penalties
Federal Injunctions
Federal Court:
Southern District of Florida
Case Summary
In April 2020, the marketers of three supplements called Neurocet, Regenify, and Resetigen-D settled FTC charges that they deceptively promoted their products to older Americans using false claims that their products could stop pain and treat age-related ailments. The proposed order bars the defendants-five related companies and their principals from making any claims about the health benefits of their products unless they are true and supported by scientific evidence. In October 2021, the FTC announced it was returning $1.1 million to consumer who bought the defendants' products.